|
|
|
|
|
|
|
|
ScienceDirect.com - Journal of Pain and Symptom Management - A Spicamycin Derivative (KRN5500) Provides Neuropathic Pain Relief in Patients With Advanced Cancer: A Placebo-Controlled, Proof-of-Concept Trial
Conclusion
This
proof-of-concept study for KRN5500 in patients with advanced cancer and
any type of neuropathic pain found gastrointestinal adverse events to
be the predominant safety concern. The results also provided the first
indication of clinical and statistical efficacy in reducing pain
intensity.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.